Lynne Kaminer to Middle Aged
This is a "connection" page, showing publications Lynne Kaminer has written about Middle Aged.
Connection Strength
0.082
-
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. Leuk Res. 2021 12; 111:106736.
Score: 0.012
-
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Br J Haematol. 2014 Jun; 165(6):793-800.
Score: 0.007
-
Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. Cancer. 1990 Jun 15; 65(12):2619-23.
Score: 0.006
-
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2009 Sep; 50(9):1434-41.
Score: 0.005
-
High dose chemotherapy with autologous hematopoietic stem cell support in the treatment of refractory stage IV breast carcinoma. Bone Marrow Transplant. 1989 Jul; 4(4):359-62.
Score: 0.005
-
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann Oncol. 2007 Apr; 18(4):679-88.
Score: 0.004
-
Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? Bone Marrow Transplant. 2006 Jul; 38(2):95-100.
Score: 0.004
-
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol. 2006 Apr; 8(2):183-8.
Score: 0.004
-
Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 Mar; 37(6):553-7.
Score: 0.004
-
Oxaliplatin-related acute myelogenous leukemia. Oncologist. 2006 Mar; 11(3):261-2.
Score: 0.004
-
Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scand J Infect Dis. 2006; 38(4):290-2.
Score: 0.004
-
Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998). Leukemia. 2004 Oct; 18(10):1605-10.
Score: 0.004
-
Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004 Oct; 45(10):2047-55.
Score: 0.004
-
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol. 2003 Nov; 65(2):127-34.
Score: 0.004
-
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro Oncol. 2000 04; 2(2):114-9.
Score: 0.003
-
Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol. 1999 Feb; 10(2):177-82.
Score: 0.003
-
High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. J Natl Cancer Inst. 1990 Jan 03; 82(1):29-34.
Score: 0.001
-
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987 Nov; 70(5):1412-7.
Score: 0.001
-
A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol. 1987 Feb; 5(2):260-5.
Score: 0.001